Company news

Mesoblast Limited news in 2024

Mesoblast Limited's news releases, calls and decks from 2024, newest first.

View company

FDA Approves Mesoblast Ryoncil

December 18, 2024

Material Announcement

December 5, 2024

Pause in Trade

December 4, 2024

FDA Grants Mesoblast RMAT Designation

December 4, 2024

Response to ASX Price Query

November 14, 2024

Class Action Resolution

August 21, 2024

FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

July 23, 2024

Mesoblast Resubmits BLA with FDA for Ryoncil Approval

July 9, 2024

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

March 26, 2024

Mesoblast Completes Placement and Entitlement Offer

March 13, 2024

FDA Supports Accelerated Approval Pathway for Heart Failure

March 10, 2024

MSB Q2 Financial Results and Operational Highlights

February 28, 2024

Half Year Financial Results Presentation

February 28, 2024

FDA Grants Orphan Drug Designation for Revascor

February 15, 2024

FDA Grants Rare Pediatric Disease Designation for Revascor

January 18, 2024

Calls in 2024

Decks in 2024